ArticleEuropean journal of clinical pharmacology2012

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin.

Teddy Kosoglou et al.PubMed ↗Publisher ↗

No numbers read from the abstract.